Iterion Therapeutics   Report issue

For profit Phase 2
Founded: Houston TX United States (2014)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2018
NCT03459469
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Beta Cat Pharmaceuticals, Inc. | Iterion Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (2)

pembrolizumab (keytruda) (1 trial)

tegavivint (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibromatosis, Aggressive (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2